研究者詳細 - 齋藤　竜太

論文 - 齋藤　竜太

分割表示 361 件中 301 - 320 件目／全件表示 >>

Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.

Osada Y, Saito R, Miyata S, Shoji T, Shibahara I, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T

Brain tumor pathology 38 巻 ( 3 ) 頁： 218 - 227 2021年7月

頭蓋内胚腫治療後にてんかんを発症した症例群の検討

下田由輝, 金森政之, 大沢伸一郎, 齋藤竜太, 園田順彦, 隈部俊宏, 中里信和, 冨永悌二

てんかん研究 39 巻 ( 2 ) 頁： 305 - 305 2021年7月

Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping 国際誌

Motomura, K; Chalise, L; Ohka, F; Aoki, K; Tanahashi, K; Hirano, M; Nishikawa, T; Yamaguchi, J; Shimizu, H; Wakabayashi, T; Saito, R

JOURNAL OF NEURO-ONCOLOGY 153 巻 ( 2 ) 頁： 361 - 372 2021年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Neuro-Oncology

Purpose: The aim of this study was to assess the effect of the extent of resection (EOR) of tumors on survival in a series of patients with grade II and III gliomas (GII/III-gliomas) who underwent awake brain mapping. Methods: We retrospectively analyzed 126 patients with GII/III-gliomas in the dominant and non-dominant hemisphere who underwent awake brain surgery at the same institution between December 2012 and May 2020. Results: EOR cut-off values for improved progression-free survival (PFS) were determined by a receiver operator characteristic (ROC) analysis of 5-year PFS. The ROC for EOR showed a cut-off value of ≥ 85.3%. The median PFS rate of patients with GII/III-gliomas in the group with an EOR ≥ 100%, including supratotal resection (n = 47; median survival [MS], not reached), was significantly higher than that in the group with an EOR < 90% (n = 52; MS, 43.1 months; 95% CI 37.7–48.5 months; p = 0.03). In patients with diffuse astrocytomas and anaplastic astrocytomas, the group with EOR ≥ 100%, including supratotal resection (n = 25; MS, not reached), demonstrated a significantly better PFS rate than did the group with an EOR < 100% (n = 45; MS, 35.8 months; 95% CI 19.9–51.6 months; p = 0.03). Supratotal or gross total resection was correlated with better PFS in IDH-mutant type of diffuse astrocytomas and anaplastic astrocytomas (n = 19; MS, not reached vs. n = 35; MS, 40.6 months; 95% CI 22.3–59.0 months; p = 0.02). By contrast, supratotal or gross total resection was not associated with longer PFS rates in patients with IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas. Conclusions: The present study demonstrates a significant association between tumor EOR and survival in patients with GII/III gliomas. The EOR cut-off value for 5-year PFS was ≥ 85.3%. It is noteworthy that supratotal or gross total resection significantly correlated with better PFS in IDH-mutant type of WHO grade II and III astrocytic tumors. In light of our finding that EOR did not correlate with PFS in patients with aggressive IDH-wild type of diffuse astrocytomas and anaplastic astrocytomas, we suggest treatments that are more intensive will be needed for the control of these tumors.

DOI： 10.1007/s11060-021-03776-w

Postcentral gyrus resection of opercular gliomas is a risk factor for motor deficits caused by damaging the radiologically invisible arteries supplying the descending motor pathway. 国際誌

Shibahara I, Sato S, Hide T, Saito R, Kanamori M, Sonoda Y, Tominaga T, Kumabe T

Acta neurochirurgica 163 巻 ( 5 ) 頁： 1269 - 1278 2021年5月

[Chemotherapy for Glioma].

Saito R

No shinkei geka. Neurological surgery 49 巻 ( 3 ) 頁： 588 - 596 2021年5月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：株式会社医学書院

Chemotherapeutic treatment of malignant gliomas is extremely challenging. Tumor accumulation of systemically-administrated chemotherapy is always hindered by the blood-brain barrier(BBB). Although temozolomide administered orally or intravenously represents the standard of care for malignant gliomas, its efficacy is unsatisfactory. Local chemotherapy bypasses the BBB and, therefore, achieves a high drug concentration at the site the drug is administered. Carmustine wafers are clinically available local chemotherapeutic agents. However, their efficacy is limited because of limited drug penetration into the tumor. Combined with the highly chemoresistant features of glioma itself, ongoing chemotherapy is far from satisfactory in terms of efficacy. This review covers several important issues regarding temozolomide chemotherapy, including the reactivation of hepatitis B virus, assessment of

DOI： 10.11477/mf.1436204432

PubMed

CiNii Research

researchmap

高速リアルタイムPCR法を用いた迅速IDH1、H3F3A、BRAF遺伝子変異解析

大岡史治, 北野詳太郎, 本村和也, 清水浩之, 棚橋邦明, 青木恒介, 平野雅規, 山口純矢, 夏目敦至, 齋藤竜太

Brain Tumor Pathology 38 巻 ( Suppl. ) 頁： 075 - 075 2021年5月

側脳室下角に存在する脈絡叢腫瘍に対する島下境界溝を介した摘出術

柴原一陽, 百武佑理, 豊田茉梨子, 半田肇, 猿田和貴子, 犬飼円, 佐藤澄人, 秀拓一郎, 齋藤竜太, 金森政之, 園田順彦, 冨永悌二, 隈部俊宏

小児の脳神経 46 巻 ( 2 ) 頁： 179 - 179 2021年4月

Effect of endoscope flexibility on tissue dissection profile assessed with pulsed water jet device: ensuring safety, efficacy, and handling of thin devices for neuroendoscopic surgery. 国際誌

Kusunoki T, Kawaguchi T, Nakagawa A, Noguchi Y, Osawa SI, Endo H, Endo T, Saito R, Kanamori M, Niizuma K, Tominaga T

BMC research notes 14 巻 ( 1 ) 頁： 64 - 64 2021年2月

Hepatitis B virus reactivation during temozolomide administration for malignant glioma.

Shoji T, Kanamori M, Inoue J, Saito R, Osada Y, Shimoda Y, Chonan M, Uenohara H, Masamune A, Tominaga T

International journal of clinical oncology 26 巻 ( 2 ) 頁： 305 - 315 2021年2月

H3K27M and <i>TERT</i> promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma. 国際誌

Osada Y, Saito R, Shibahara I, Sasaki K, Shoji T, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T

Neuro-oncology advances 3 巻 ( 1 ) 頁： vdab038 2021年1月

覚醒下手術中痙攣発作コントロールにおけるレベチラセタム・ペランパネル併用療法の有効性について

本村和也, 齋藤竜太

神経治療学 38 巻 ( 6 ) 頁： S211 - S211 2021年

アクセス困難な硬膜動静脈瘻症例における，対側上錐体静脈洞を経由する上錐体静脈洞へのアプローチ

鈴木啓太, 西堀正洋, 泉孝嗣, 鈴木宰, 武藤学, 荒木芳生, 宇田憲司, 横山欣也, 齋藤竜太

脳血管内治療 6 巻 ( 3 ) 頁： 161 - 168 2021年

記述言語：日本語出版者・発行元：特定非営利活動法人日本脳神経血管内治療学会

<p>【目的】多発硬膜動静脈瘻（dural arteriovenous fistula: DAVF）の症例において，左上錐体静脈洞部（superior petrosal sinus: SPS）のシャントを右 SPS 経由で塞栓した症例を報告する．【症例】60 歳女性，意識障害の精査にて深部静脈逆流を伴う多発 DAVF を認めた．逆流に最も関与する左横静脈洞部 DAVF に対して経静脈的塞栓術を施行した．術後症状改善が乏しく，再度DSA を行うと，左 SPS へのシャントと深部静脈への逆流が明らかとなった．左横静脈洞と両側下錐体静脈洞は閉塞していたため，右 SPS と両側海綿静脈洞を経由してマイクロカテーテルをシャント部へ誘導し，左 SPS を塞栓し，逆流の消失を得た．【結論】対側 SPS を経由した SPS へのアクセスは，同側からのアクセスが困難な症例において，有効な選択肢になり得る．</p>

DOI： 10.20626/nkc.tn.2021-0009

CiNii Research

researchmap

Corpus Callosum Swelling after Resection of Intraventricular Central Neurocytoma.

Aburakawa D, Kanamori M, Akashi T, Sato S, Saito R, Tominaga T

NMC case report journal 8 巻 ( 1 ) 頁： 535 - 543 2021年

Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review.

Yamaguchi J, Motomura K, Ohka F, Aoki K, Tanahashi K, Hirano M, Chalise L, Nishikawa T, Shimizu H, Natsume A, Wakabayashi T, Saito R

NMC case report journal 8 巻 ( 1 ) 頁： 747 - 753 2021年

Postoperative Cervicothoracic Kyphosis Following Infantile Intramedullary Tumor Resection Accelerates Neurological Deterioration.

Gonda T, Nagashima Y, Nishimura Y, Ito H, Nisii T, Oyama T, Hara M, Saito R

NMC case report journal 8 巻 ( 1 ) 頁： 705 - 711 2021年

Management of Asymptomatic Vertebral Artery Injury Caused by a Cervical Pedicle Screw Malposition: Two Case Reports.

Otsuka T, Izumi T, Nishihori M, Tsukada T, Araki Y, Yokoyama K, Uda K, Goto S, Ikezawa M, Kato N, Nakano M, Saito R

NMC case report journal 8 巻 ( 1 ) 頁： 713 - 717 2021年

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations 国際誌

Hideyuki Arita, Yuko Matsushita, Ryunosuke Machida, Kai Yamasaki, Nobuhiro Hata, Makoto Ohno, Shigeru Yamaguchi, Takashi Sasayama, Shota Tanaka, Fumi Higuchi, Toshihiko Iuchi, Kuniaki Saito, Masayuki Kanamori, Ken ichiro Matsuda, Yohei Miyake, Kaoru Tamura, Sho Tamai, Taishi Nakamura, Takehiro Uda, Yoshiko Okita, Junya Fukai, Daisuke Sakamoto, Yasuhiko Hattori, Eriel Sandika Pareira, Ryusuke Hatae, Yukitomo Ishi, Yasuji Miyakita, Kazuhiro Tanaka, Shunsaku Takayanagi, Ryohei Otani, Tsukasa Sakaida, Keiichi Kobayashi, Ryuta Saito, Kazuhiko Kurozumi, Tomoko Shofuda, Masahiro Nonaka, Hiroyoshi Suzuki, Makoto Shibuya, Takashi Komori, Hikaru Sasaki, Masahiro Mizoguchi, Haruhiko Kishima, Mitsutoshi Nakada, Yukihiko Sonoda, Teiji Tominaga, Motoo Nagane, Ryo Nishikawa, Yonehiro Kanemura, Aya Kuchiba, Yoshitaka Narita, Koichi Ichimura

Acta Neuropathologica Communications 8 巻 ( 1 ) 頁： 201 - 201 2020年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of TERT promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both TERT promoter mutation and 1p/19q codeletion, while 30 had either TERT promoter mutation (n = 24) or 1p/19q codeletion (n = 6) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, TERT promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90–100%) were associated with favorable prognosis (p < 0.05). A multivariable Cox regression model revealed that TERT promoter mutation had a significantly favorable prognostic impact (hazard ratio = 0.421, p = 0.049), while 1p/19q codeletion did not have a significant impact (hazard ratio = 0.648, p = 0.349). Analyses incorporating patient clinical and genetic information were further conducted to identify subgroups showing the favorable prognostic impact of TERT promoter mutation. Among the grade II-III glioma patients with a KPS score of 90 or 100, those with IDH-TERT co-mutation and intact 1p/19q (n = 17) showed significantly longer survival than those with IDH mutation, wild-type TERT, and intact 1p/19q (n = 185) (5-year overall survival, 94% and 77%, respectively; p = 0.032). Our results demonstrate that TERT promoter mutation predicts favorable prognosis independent of 1p/19q codeletion in IDH-mutated gliomas. Combined with its adverse effect on survival among IDH-wild glioma cases, the bivalent prognostic impact of TERT promoter mutation may help further refine the molecular diagnosis and prognostication of diffuse gliomas.

DOI： 10.1186/s40478-020-01078-2

Scopus

PubMed

researchmap

A multinodular and vacuolating neuronal tumor in the right temporal lobe with positive methionine uptake: A case report

Taketo Nishizawa, Ryuta Saito, Masashi Chonan, Masayuki Kanamori, Kentaro Takanami, Mika Watanabe, Teiji Tominaga

Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 22 巻 2020年12月

掲載種別：研究論文（学術雑誌）

Multinodular and vacuolating neuronal tumor (MVNT) is a recently recognized type of neural tumor that was first documented in 2013. This tumor type is characterized by multiple nodules of neuronal cells with vacuolar degeneration localized in the subcortical white matter. Here, we report a case of MVNT in the right temporal lobe of a 26-year-old female. Magnetic resonance imaging (MRI) revealed a high-intensity lesion on a T2- weighted image of the right temporal lobe without contrast enhancement. Positron emission tomography revealed increased 11C-methionine uptake in the lesion, which was pathologically diagnosed as MVNT.

DOI： 10.1016/j.inat.2020.100861

Scopus

researchmap

がん遺伝子パネル検査でSMARCB1変異を認め、INI-1蛋白陽性のAT/RTと考えられた一例(Clinical sequencing revealed two distinct mutations in SMARCB1, in an INI-1 positive AT/RT)

Kaino Akira, Niizuma Hidetaka, Moriya Kunihiko, Katayama Saori, Irie Masahiro, Rikiishi Takeshi, Saito Ryuta, Kanamori Masayuki, Sasahara Yoji, Kure Shigeo

日本小児血液・がん学会雑誌 57 巻 ( 4 ) 頁： 245 - 245 2020年10月

Orengedokuto and shosaikoto for intractable intracranial carmustine implant-induced fever in a patient with brain tumor: A case report. 国際誌

Suzuki S, Takayama S, Kikuchi A, Arita R, Abe M, Saito R, Kanamori M, Tominaga T, Ishii T

Explore (New York, N.Y.) 17 巻 ( 3 ) 頁： 236 - 238 2020年8月

　前のページ - 次のページ　

<齋藤 竜太>

論文 - 齋藤 竜太

<齋藤　竜太>

論文 - 齋藤　竜太